The liver plays several critical roles in the metabolic adaptation to fasting. We have shown previously that the transcriptional coactivator peroxisome proliferator-activated receptor ␥ coactivator-1␣ (PGC-1␣) is induced in fasted or diabetic liver and activates the entire program of gluconeogenesis. PGC-1␣ interacts with several nuclear receptors known to bind gluconeogenic promoters including the glucocorticoid receptor, hepatocyte nuclear factor 4␣ (HNF4␣), and the peroxisome proliferator-activated receptors. However, the genetic requirement for any of these interactions has not been determined. Using hepatocytes from mice lacking HNF4␣ in the liver, we show here that PGC-1␣ completely loses its ability to activate key genes of gluconeogenesis such as phosphoenolpyruvate carboxykinase and glucose-6-phosphatase when HNF4␣ is absent. It is also shown that PGC-1␣ can induce genes of ␤-oxidation and ketogenesis in hepatocytes, but these effects do not require HNF4␣. Analysis of the glucose-6-phosphatase promoter indicates a key role for HNF4␣-binding sites that function robustly only when HNF4␣ is coactivated by PGC-1␣. These data illustrate the involvement of PGC-1␣ in several aspects of the hepatic fasting response and show that HNF4␣ is a critical component of PGC-1␣-mediated gluconeogenesis.
A crucial function of the liver is the regulation of systemic fuel availability. During prolonged fasting, the liver activates gluconeogenesis to maintain blood glucose levels. Gluconeogenesis begins 4-6 h after the onset of fasting and reaches maximal activity as hepatic glycogen stores are reduced. Fatty acid oxidation is also activated during fasting and provides ATP for the liver. The very rapid oxidation of fatty acids also leads to generation and export of ketone bodies, which provide an important alternative fuel source to glucose, especially for the central nervous system. Gluconeogenesis, ␤-oxidation of fatty acids, and ketogenesis all are suppressed by insulin and elevated in poorly controlled diabetes. Elevated gluconeogenesis is a major contributor to the hyperglycemia of diabetes.
Peroxisome proliferator-activated receptor (PPAR)␥ coactivator-1␣ (PGC-1␣) is a transcriptional coactivator that regulates a wide range of processes involved in energy production and utilization, namely adaptive thermogenesis, mitochondrial biogenesis, glucose uptake in muscle, and skeletal muscle fiber-type switching (1) (2) (3) (4) . PGC-1␣ is induced in the liver in fasting or diabetes and is a potent stimulator of the entire program of hepatic gluconeogenesis (5, 6) . Primary murine hepatocytes and rats receiving recombinant PGC-1␣ through adenoviral delivery exhibit a dramatic rise in the expression of key gluconeogenic enzymes in the liver, such as phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase), and in the subsequent production of glucose. The function of PGC-1␣ in other aspects of the hepatic fasting response is unknown, although PGC-1␣ has been shown to induce mitochondrial fatty acid oxidation in cardiac myocytes (7, 8) .
As a multifaceted regulator of energy metabolism, PGC-1␣ demonstrates binding to several nuclear hormone receptors as well as other transcription factors. With regard to gluconeogenesis, preliminary analysis of the PEPCK promoter suggests that PGC-1␣ functions through several nuclear receptors: the glucocorticoid receptor, hepatocyte nuclear factor 4␣ (HNF4␣), PPAR␣, and PPAR␥ (5, (9) (10) (11) (12) . The interaction of PGC-1␣ with glucocorticoid receptor and HNF4␣ requires the major LXXLL motif of this coactivator and utilizes the AF2 domain of each receptor. Because the analysis of PGC-1␣ action on gluconeogenic promoters to date has been entirely of the gain-of-function variety, a critical question is: Which of these interactions are required for the activation of gluconeogenesis? Given that this process occurs mainly in the liver and HNF4␣ is the only liver-enriched component implicated thus far with PGC-1␣, we focused our studies on this protein.
A total knockout of HNF4␣ is embryonic-lethal, but mice lacking HNF4␣ selectively in the liver are viable for several weeks, although they suffer from defective lipid homeostasis and weight loss (13) . By using primary hepatocytes isolated from control (HNF4␣ f lox) and HNF4␣ liver-specific knockout mice (13) , the ability of PGC-1␣ to activate components of the fasting response in these cells in the presence and absence of HNF4␣ was analyzed. These studies demonstrate that HNF4␣ is absolutely required for PGC-1␣ to induce the expression of the key gluconeogenic genes PEPCK and G6Pase. Furthermore, we show that PGC-1␣ is capable of inducing several genes of ␤-oxidation and ketogenesis in the liver, but these processes, unlike gluconeogenesis, do not depend on HNF4␣.
Materials and Methods
Animal Experiments. All animal experiments were performed in accordance with Association for Assessment and Accreditation of Laboratory Animal Care guidelines and approved by institutional committees at the Dana Farber Cancer Institute and the National Cancer Institute. For the fasting time-course experiment, 45-day-old mice were either fed ad libitum or subjected to 14-, 24-, or 48-h fasts that began during the dark period. Animals then were killed by CO 2 asphyxiation, and their livers were harvested. Livers were snap-frozen in liquid nitrogen and stored at Ϫ80°C. RNA was collected from aliquots of frozen liver by using Trizol reagent (Invitrogen) and then analyzed by Northern blotting with specific cDNA probes.
Cell Culture. Primary mouse hepatocytes were isolated as described (14) and cultured in Williams' E medium containing 10% FBS and 2% DMSO at 37°C in 5% CO 2 . Murine hepatocytes transformed by simian virus 40 (SV40) large T antigen were Abbreviations: PPAR, peroxisome proliferator-activated receptor; PGC-1␣, PPAR␥ coactivator-1␣; PEPCK, phosphoenolpyruvate carboxykinase; G6Pase, glucose-6-phosphatase; HNF4␣, hepatocyte nuclear factor 4␣; SV40, simian virus 40; IRU, insulin response unit. ‡ To whom correspondence should be addressed. E-mail: brucespiegelman@dfci. harvard.edu. cultured at 33°C in 5% CO 2 in ␣-MEM with 2 mM glutamine͞10 nM dexamethasone͞10% FBS.
Adenovirus Infection. Primary hepatocytes were infected 14 h after plating with adenoviruses expressing either GFP alone or GFP and PGC-1␣ at an multiplicity of infection of 50 (7). Twenty-four hours after infection, fresh growth medium containing 500 nM cAMP and 1 mM dexamethasone was added. Forty-eight hours after infection, cells were harvested for RNA isolation and Northern blotting with specific cDNA probes.
Plasmids. PGC-1␣ plasmids (15) and the Ϫ1227͞ϩ57 and Ϫ180͞ ϩ57 G6Pase luciferase reporter constructs have been described (16, 17) . G6Pase constructs (Ϫ470͞ϩ57 and Ϫ298͞ϩ57) were made through restriction digest followed by Klenow fill-in reactions and blunt-end ligations. The region between Ϫ1227 and Ϫ470 was removed through a KpnI͞BstX I double digest, and the region between Ϫ1227 and Ϫ298 was removed through a SacI͞ TthIII I double digest. Mutants A-D of the G6Pase promoter were made by using the QuikChange site-directed mutagenesis kit (Stratagene).
Transcriptional Activation Assays. Transformed mouse hepatocytes were transiently transfected by using Superfect (Qiagen, Valencia, CA) at 60% confluence. After a 2-to 3-h incubation, fresh growth medium was added. Cells were lysed 24 h posttransfection, and aliquots were used to measure ␤-galactosidase (as a transfection control) and luciferase activities.
Gel-Shift Assays. The sequences of each oligonucleotide corresponding to sites A-D are 5Ј-CCAGGAGGGCAGACCCTTG-CACTGCCAAGAAGC-3Ј (A), 5Ј-ATGTAGACTCTGTCCT-GTGTCTCTGGCCTGGTA-3Ј (B), 5Ј-GCCAAGAAGC-ATGCCAAAGTTAATCATTGGCCC-3Ј (C), and 5Ј-GGC-CCTGCTGAGTACATGGCCGATCAGGCTGT T-3Ј (D). Each 5Ј 3 3Ј oligonucleotide (Integrated DNA Technologies, Coralville, IA) was 32 PO 4 -labeled by using T4 DNA polynucleotide kinase and then annealed to an excess of its unlabeled 3Ј 3 5Ј complementary oligonucleotide. Radiolabeled duplex probes were spun through a G50 column and then incubated with in vitro-transcribed͞translated proteins and antibodies for 20 min at 4°C in a buffer containing 12% glycerol, 12 mM Hepes (pH 7.9), 4 mM Tris (pH 7.9), 60 mM KCl, 1 mM EDTA, and 1 mM DTT. Complexes were resolved on a 4.5% acrylamide Trisglycine gel. Antibodies against HNF4␣ and HNF3␤ (used as a nonspecific antibody) were from Santa Cruz Biotechnology.
Results and Discussion
We first examined mice lacking liver HNF4␣ for the expression of gluconeogenic genes under conditions of feeding and fasting. Previous studies of mice lacking HNF4␣ in the liver revealed defects in lipid homeostasis, but gluconeogenesis was not investigated (13) . As seen in Fig. 1 and as expected, fasting increases levels of mRNAs encoding the enzymes PEPCK and G6Pase in control mice (f lox) at all time points. However, mice lacking HNF4␣ in the liver fail to induce PEPCK and G6Pase mRNA to any significant extent after the same periods of food deprivation. This shows that HNF4␣ is required for activating the genes of gluconeogenesis during fasting. Fig. 1 also shows, as expected, that PGC-1␣ is induced in the liver of the control (f lox) mice under fasting conditions. Interestingly, the level of PGC-1␣ mRNA in the fed state and at all time points during the fast is greater in livers lacking HNF4␣ as compared with control livers. These data suggest an unexpected role for HNF4␣ as a regulator of PGC-1␣ as well as a target of this coactivator. Whether this effect of HNF4␣ is mediated through direct actions on the PGC-1␣ promoter or through more indirect actions is not known. In either case, the elevation in PGC-1␣ expression could represent part of a physiological system to compensate for the absence of HNF4␣ in these mice.
To investigate the requirement for HNF4␣ in PGC-1␣ function, primary hepatocytes were isolated from HNF4␣ liverspecific knockout mice and from control (HNF4␣ flox) mice, which then were infected with adenovirus encoding either GFP alone or GFP plus PGC-1␣. Fig. 2 Top demonstrates that, as shown previously, expression of PGC-1␣ in control primary hepatocytes powerfully induces the expression of PEPCK and G6Pase mRNA (5) . In marked contrast, infection of adenoviral PGC-1␣ into hepatocytes lacking HNF4␣ fails to elicit any detectable expression of either of these genes despite equivalent expression of PGC-1␣ mRNA. This indicates that PGC-1␣'s regulation of the genes encoding these gluconeogenic enzymes completely depends on HNF4␣.
We next tested whether PGC-1␣ can regulate other aspects of the fasting response in the liver and whether these pathways also require HNF4␣. Carnitine palmitoyl transferase 1 and medium-chain acyl-CoA dehydrogenase are two enzymes essential for the mitochondrial transport and ␤-oxidation of fatty acids. As seen in Fig. 2 Middle, the infection of primary hepatocytes with adenoviral PGC-1␣ strongly induces mRNAs for both of these genes. These inductions, unlike that of the gluconeogenic program, are observed in both the HNF4␣ f lox Fig. 1. HNF4␣ is required for gluconeogenesis. Control (HNF4␣ flox) mice or mice lacking liver HNF4␣ were fed ad libitum or fasted for 14, 24, or 48 h. RNA taken from the livers of these mice was analyzed for HNF4␣, PEPCK, G6Pase, and PGC-1␣. GAPDH was blotted to verify equal loading.
hepatocytes and the HNF4␣ null hepatocytes, although there is a slight decrease in carnitine palmitoyl transferase 1 expression in the latter. Ketone body synthesis requires the expression of 3-ketothiolase, 3-hydroxy-3-methylglutaryl-CoA synthase, and 3-hydroxy-3-methylglutaryl-CoA lyase. These enzymes catalyze the conversion of acetyl CoA, the end product of ␤-oxidation, into ketone bodies. Fig. 2 Bottom demonstrates that expression of PGC-1␣ potently increases mRNA levels for 3-ketothiolase and 3-hydroxy-3-methylglutaryl-CoA lyase. This transcriptional coactivation does not depend on HNF4␣, because the induction of these genes by PGC-1␣ is observed in both the control and knockout cells. These data indicate that PGC-1␣ can induce several key aspects of the liver's response to fasting, but only expression of the gluconeogenic genes depends on HNF4␣.
PGC-1␣ interacts with HNF4␣ through a well defined response element on the PEPCK promoter (5, 10). However, the role of HNF4␣ in the hormonal and fasting induction of G6Pase through its promoter remains unclear. Based on the data presented above, we sought to determine how PGC-1␣ and HNF4␣ cooperate to regulate the expression of this gluconeogenic gene. By using a reporter plasmid containing 1.2 kb of the human G6Pase promoter placed upstream of the luciferase gene (Ϫ1227͞ϩ57 G6Pase Luc), transient transfection assays were conducted in hepatocytes transformed with SV40 large T antigen (18) . Transfection of a plasmid expressing either PGC-1␣ or HNF4␣ activates this promoter very poorly (Fig. 3A) . However, cotransfection of PGC-1␣ and HNF4␣ together causes a dramatic activation of this promoter by at least 20-fold. These data suggest that although HNF4␣ cannot activate the G6Pase promoter by itself, it can do so quite effectively in combination with PGC-1␣. This function of HNF4␣, in principle, could be through direct binding to the promoter or through the regulation of other factors known to bind the G6Pase promoter.
FOXO1, an important regulator of G6Pase expression, is a member of the forkhead group of transcription factors that has been shown to be a key target for insulin suppression of gluconeogenesis (17, 19, 20) . The insulin response unit (IRU) between Ϫ196 and Ϫ156 in the human G6Pase promoter contains three well characterized FOXO1-binding sites (17, 21) . Because FOXO1 interacts with many nuclear hormone receptors including glucocorticoid receptor, thyroid receptor, and estrogen receptor (22), we first considered the possibility that HNF4␣ may regulate G6Pase expression by forming a complex with FOXO1 and PGC-1␣ on the IRU. However, HNF4␣ and PGC-1␣ are able to coactivate a mutant version of the reporter lacking FOXO1-binding sites (mIRU) as well as they coactivate the wild-type reporter (Fig. 3A) . In contrast, the mutant IRU promoter is completely unresponsive to FOXO1 (ref. 17 and data not shown).
To investigate more systematically sites on the G6Pase promoter responsive to coactivation of HNF4␣ by PGC-1␣, a series of deletion mutants from the parent (Ϫ1227͞ϩ57) G6Pase promoter-luciferase vehicle was constructed. Cotransfected HNF4␣ and PGC-1␣ robustly activate promoters originating at nucleotides Ϫ470 and Ϫ298 (Fig. 3B) . However, there is a 90% decrease in coactivation of HNF4␣ when the region between Ϫ298 and Ϫ180 is removed, suggesting that this short segment of DNA contains sites through which HNF4␣ functions with PGC-1␣.
This region of the G6Pase promoter (Ϫ298͞Ϫ180) was analyzed by NUBISCAN 1.0PB, a computer algorithm that predicts nuclear receptor response elements by using a weighted matrix of single hexamer half-sites (23) . A search for potential HNF4␣-binding sites (DR1) in this region of the G6Pase promoter was conducted, and the four highest-scoring sites are listed in Fig. 4A . To determine whether each of these sites bind HNF4␣, we performed electrophoretic mobility-shift assays. Radiolabeled duplex probes were designed to encompass each of the 13-bp sites, identified above, surrounded by 10-bp f lanking sequences. After the addition of in vitro-transcribed͞ translated HNF4␣ to each probe, a specific complex is clearly visible on sites A and B (Fig. 4B) . This complex is supershifted by the addition of an antibody raised against HNF4␣. No specific HNF4␣ complex is detected on sites C and D. The functional significance of these HNF4␣-binding sites was determined by mutating each one within the context of the parent G6Pase promoter. Fig. 4 A shows the nucleotides that were subjected to point mutation in sites A-D. The ability of PGC-1␣ to coactivate HNF4␣ decreases 30% and 70% when sites A and B, respectively, are mutated (Fig. 4C ). There is little or no effect on the activity of HNF4␣ in combination with PGC-1␣ when sites C and D are mutated. These data, in total, suggest that HNF4␣ by itself is a poor activator of the G6Pase promoter, but two distinct HNF4␣ sites can function to activate this promoter when PGC-1␣ is present.
Gluconeogenesis is a major contributing factor in the hyperglycemia of both type I and type II diabetes. It therefore is critical that we develop a better understanding of the molec- Fig. 2 . PGC-1␣ requires HNF4␣ to induce the genes of gluconeogenesis. Primary hepatocytes taken from control and liver HNF4␣ knockout mice were infected with adenovirus encoding either GFP or PGC-1␣ as described in Materials and Methods. RNA was subsequently harvested and analyzed for the expression of gluconeogenic, ␤-oxidative, and ketogenic markers. 36B4 was blotted as an equal loading control. CPT1, carnitine palmitoyl transferase 1; MCAD, medium-chain acyl-CoA dehydrogenase; HMG-CoA lyase, 3-hydroxy-3-methylglutaryl-CoA lyase. ular mechanisms driving this process to facilitate the development of improved therapies. We have shown previously that PGC-1␣ is increased in the liver during fasting and in multiple animal models of diabetes (5) . Expression of this coactivator in cultured liver cells or in livers of live rats at physiological levels is sufficient to activate the entire program of gluconeogenesis. Although PGC-1␣ can interact with and coactivate the glucocorticoid receptor, HNF4␣, and the PPARs on promoters of genes involved in gluconeogenesis, no data are available concerning the relative requirement for any of these transcription factors. Using hepatocytes deficient in HNF4␣, we show that PGC-1␣ completely loses its ability to activate genes of gluconeogenesis, namely PEPCK and G6Pase, in the absence of this liver-enriched nuclear receptor. Analysis of the G6Pase promoter indicates that PGC-1␣ functions, in large measure, through HNF4␣-binding sites that have detectable activity only in the presence of both HNF4␣ and PGC-1␣. Mutation of these sites significantly impairs PGC-1␣ coactivation but does not completely abrogate it. Because HNF4␣ is known to induce HNF1␣ in hepatocytes (24, 25) , it is possible that some degree of PGC-1␣ coactivation may occur through an HNF1␣-binding site in the G6Pase promoter (26 -28) . It is also possible that PGC-1␣ is acting in part through other HNF4␣-binding sites outside the region of the G6Pase promoter studied here; indeed, a functional site for HNF4␣ distinct from those described here has been found recently at Ϫ76 of the mouse G6Pase promoter (29) .
Although HNF4␣ is absolutely required for PGC-1␣-mediated induction of PEPCK and G6Pase mRNA, it is very likely that this coactivator also requires other transcription factors known to bind the complex promoters of these genes. Recent data suggest that PGC-1␣ also binds to and coactivates FOXO1 through the IRU of the G6Pase promoter (P.P., unpublished data). The PEPCK promoter is also activated by an array of accessory factors and receptors that require precise positioning in order for maximal induction to occur (30) . For example, the binding of HNF4␣ on this promoter has been shown to facilitate the binding of the glucocorticoid receptor on nonconsensus glucocorticoid response elements (31) . It is likely that PGC-1␣ plays a critical and dynamic role in modulating these interactions and multiprotein assembly.
The role of the liver in metabolic adaptation to the fasted state extends beyond gluconeogenesis to ␤-oxidation of fatty acids and ketogenesis. We show here that PGC-1␣ can induce several key genes of both of these processes in primary hepatocytes. Hence, PGC-1␣ may be viewed as a more general mediator of the fasted state in the liver. Interestingly, although the absence of HNF4␣ completely abrogates PGC-1␣'s induction of the gluconeogenic program, it has little or no effect on PGC-1␣'s regulation of these other hepatic pathways. This is despite previous studies showing that the promoters of the medium-chain acyl-CoA dehydrogenase and carnitine palmitoyl transferase 1 genes have binding sites for HNF4␣ (32, 33) . These data, combined with results shown here, indicate that not every binding site for HNF4␣ is a target for coactivation by PGC-1␣ in vivo. The induction of the ␤-oxidation genes by PGC-1␣ in the absence of HNF4␣ likely occurs through other transcription factors such as PPAR␣ and the estrogen-related receptor ␣ (8, 34 -38) . Likewise, hepatic thiolase has been identified as a target of PPAR␣ transactivation (39) . Similar genetic analysis of these pathways to determine the factors through which PGC-1␣ is working must be performed.
The data presented here may have important therapeutic implications for both type I and type II diabetes, where inappropriately activated gluconeogenesis contributes greatly to hyperglycemia. The antidiabetic effects of the drug metformin illustrate that suppression of gluconeogenesis can have therapeutic value in this disease (40, 41) . The data presented here, in combination with previous findings (5), strongly suggest that chemical inhibition of the docking of PGC-1␣ on HNF4␣ might have important clinical effects. Although development of an inhibitor working directly at the protein-protein interface between these factors is possible, it seems far more likely that a ligand antagonist could be developed for HNF4␣ that may preferentially inhibit the docking of PGC-1␣ versus other coactivator proteins. 
